{"denoms":[{"counts":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"266"},{"groupId":"BG002","value":"312"}],"units":"Participants"}],"groups":[{"description":"Subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 of 28 day cycle","id":"BG000","title":"Carfilzomib (A0)"},{"description":"In Cycle 1, subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16. If all doses are administered and well-tolerated over the 28-day cycle, beginning with Cycle 2 the dose will escalate to 27 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles.","id":"BG001","title":"Carfilzomib (A1)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"146"},{"groupId":"BG002","value":"172"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"120"},{"groupId":"BG002","value":"140"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"132"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"155"},{"groupId":"BG002","value":"180"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety population: The safety population consists of all enrolled patients who received at least 1 dose of carfilzomib."}